The primary objective of this study is to evaluate and compare major pathological response (MPR) rate and event-free survival (EFS) in participants receiving tislelizumab plus platinum-based doublet chemotherapy as the new additional treatment followed by tislelizumab as adjuvant treatment versus participants receiving placebo plus platinum-based doublet chemotherapy as neoadjuvant treatment followed by placebo as adjuvant treatment.
| Study Arm | Population | Intervention | Comparison | Outcome |
|---|---|---|---|---|
Resectable Stage II/ IIIA NSCLC |
Tislelizumab + Platinum-based doublet chemotherapy |
Placebo + Platinum-based doublet chemotherapy |
Primary Endpoint: MPR and EFS (by BICR) in ITT population Key Secondary Endpoints: OS, pCR, ORR, DFS, INV-assessed EFS, HRQoL, safety |
